Acute acral eruptions in children during the COVID-19 pandemic: Characteristics of 103 children and their family clusters.


Journal

Annales de dermatologie et de venereologie
ISSN: 0151-9638
Titre abrégé: Ann Dermatol Venereol
Pays: France
ID NLM: 7702013

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 21 07 2020
revised: 15 10 2020
accepted: 26 11 2020
pubmed: 9 2 2021
medline: 18 5 2021
entrez: 8 2 2021
Statut: ppublish

Résumé

A marked increase in frequency of acute acral eruptions (AAE) was observed in children during the COVID-19 pandemic in the spring period. In this observational multicenter study, based on children with AAE, we aimed to assess the proportion of household members possibly infected by SARS-CoV-2. We collected data from all children observed with AAE, prospectively from April 7, 2020 to June 22, 2020, and retrospectively since February 28, 2020. The primary outcome was the household infection rate, defined as the proportion of family clusters having at least one member with COVID-19 infection other than the child with AAE ("index child"). The definition of a case was based on characteristic clinical signs and a positive PCR or serology. The study included 103 children in 10 French departments and in Quebec. The median age was 13 years and the interquartile range [8-15], with a female-to-male ratio of 1/1.15. In children with AAE, all PCR tests were negative (n=18), and serology was positive in 2/14 (14.3%) cases. We found no significant anomalies in the lab results. A total of 66 of the 103 families (64.1%) of included children had at least one other infected member apart from the index child. The total number of household members was 292, of whom 119 (40.8%) were considered possibly infected by SARS-CoV-2. No index children or households exhibited severe COVID-19. Among the 103 households included, 64.1% had at least one infected member. Neither children with AAE nor their households showed severe COVID-19.

Sections du résumé

BACKGROUND BACKGROUND
A marked increase in frequency of acute acral eruptions (AAE) was observed in children during the COVID-19 pandemic in the spring period.
OBJECTIVES OBJECTIVE
In this observational multicenter study, based on children with AAE, we aimed to assess the proportion of household members possibly infected by SARS-CoV-2.
METHODS METHODS
We collected data from all children observed with AAE, prospectively from April 7, 2020 to June 22, 2020, and retrospectively since February 28, 2020. The primary outcome was the household infection rate, defined as the proportion of family clusters having at least one member with COVID-19 infection other than the child with AAE ("index child"). The definition of a case was based on characteristic clinical signs and a positive PCR or serology.
RESULTS RESULTS
The study included 103 children in 10 French departments and in Quebec. The median age was 13 years and the interquartile range [8-15], with a female-to-male ratio of 1/1.15. In children with AAE, all PCR tests were negative (n=18), and serology was positive in 2/14 (14.3%) cases. We found no significant anomalies in the lab results. A total of 66 of the 103 families (64.1%) of included children had at least one other infected member apart from the index child. The total number of household members was 292, of whom 119 (40.8%) were considered possibly infected by SARS-CoV-2. No index children or households exhibited severe COVID-19.
DISCUSSION CONCLUSIONS
Among the 103 households included, 64.1% had at least one infected member. Neither children with AAE nor their households showed severe COVID-19.

Identifiants

pubmed: 33551211
pii: S0151-9638(21)00005-3
doi: 10.1016/j.annder.2020.11.005
pmc: PMC7831537
pii:
doi:

Substances chimiques

Antibodies, Antinuclear 0
Immunoglobulin G 0

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-100

Informations de copyright

Copyright © 2021. Published by Elsevier Masson SAS.

Références

Pediatr Dermatol. 2020 May;37(3):437-440
pubmed: 32374033
Br J Dermatol. 2020 Jul;183(1):71-77
pubmed: 32348545
Cell. 2020 May 28;181(5):969-977
pubmed: 32437659
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Br J Dermatol. 2020 Oct;183(4):778-780
pubmed: 32585767
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Pediatr Dermatol. 2020 May;37(3):419-423
pubmed: 32396999
Br J Dermatol. 2020 Oct;183(4):729-737
pubmed: 32562567
J Pediatr. 2020 Sep;224:141-145
pubmed: 32553873
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Nature. 2020 Jul;583(7816):437-440
pubmed: 32434211
JAMA Dermatol. 2020 Sep 1;156(9):998-1003
pubmed: 32584377
Med Hypotheses. 2020 Nov;144:109959
pubmed: 32534339
JAMA Dermatol. 2021 Feb 1;157(2):202-206
pubmed: 33237291
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
Br J Dermatol. 2020 Nov;183(5):866-874
pubmed: 32628270
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2620-2629
pubmed: 32474947
J Immunol. 2015 Aug 1;195(3):865-74
pubmed: 26091718
Lancet Infect Dis. 2021 Jan;21(1):24-25
pubmed: 32437697
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):e252-e254
pubmed: 32294262
J Am Acad Dermatol. 2020 Sep;83(3):870-875
pubmed: 32502585
Pediatr Dermatol. 2020 May;37(3):406-411
pubmed: 32386460
Lancet Infect Dis. 2021 Mar;21(3):315-316
pubmed: 32563281
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824

Auteurs

T Hubiche (T)

Nice University Hospital, Department of Dermatology, 06000 Nice, France.

A Phan (A)

Lyon University Hospital, Department of Pediatric Dermatology, Hospices Civils de Lyon, 69500 Bron, France.

S Leducq (S)

Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Department of Dermatology, 37044 Tours Cedex 9, France.

J Rapp (J)

Nice University Hospital, Department of Dermatology, 06000 Nice, France.

L Fertitta (L)

AP-HP (Paris Hospitals), Paris-Necker Hospital, Department of Dermatology, 75015 Paris, France.

H Aubert (H)

Nantes University Hospital, Department of Dermatology, 44000 Nantes, France.

S Barbarot (S)

Nantes University Hospital, Department of Dermatology, 44000 Nantes, France.

C Chiaverini (C)

Nice University Hospital, Department of Dermatology, 06000 Nice, France.

B Giraudeau (B)

Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Clinical Investigation Center-INSERM 1415, 37000 Tours, France.

A Lasek (A)

Saint Vincent de Paul Hospital, Université catholique de Lille, 59000 Lille, France.

S Mallet (S)

Marseille University Hospital, Department of Dermatology, 13000 Marseille, France.

A Labarelle (A)

Marseille University Hospital, Department of Dermatology, 13000 Marseille, France.

M Piram (M)

Sainte-Justine University Hospital, Division of Dermatology, Montreal, Quebec, Canada.

C McCuaig (C)

Sainte-Justine University Hospital, Division of Dermatology, Montreal, Quebec, Canada.

L Martin (L)

Angers Hospital University, Department of Dermatology, 49000 Angers, France.

L Monitor (L)

Nancy University Hospital, Department of Dermatology, 54511 Vandœuvre-lès-Nancy, France.

I Nicol (I)

Marseille University Hospital, Department of Dermatology, 13000 Marseille, France.

M Bissuel (M)

Casamance Private Hospital, Department of Pediatrics, 13400 Aubagnes, France.

A Bellissen (A)

Marseille University Hospital, Department of Dermatology, 13000 Marseille, France.

D Jullien (D)

Lyon University Hospital, Department of Dermatology, Hospital Edouard Herriot, 69003 Lyon, France.

C Lesort (C)

Lyon University Hospital, Department of Dermatology, Hospital Edouard Herriot, 69003 Lyon, France.

P Vabres (P)

Dijon University Hospital, Department of Dermatology, 21000 Dijon, France.

A Maruani (A)

Universities of Tours and Nantes, inserm 1246-SPHERE, 37000 Tours, France; Tours University Hospital, Department of Dermatology, 37044 Tours Cedex 9, France; Tours University Hospital, Clinical Investigation Center-INSERM 1415, 37000 Tours, France. Electronic address: annabel.maruani@univ-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH